Kurse | Charts | Stammdaten | Kennzahlen | Aktion |
---|---|---|---|---|
Snapshot | Preischart | Daten + Gebühr | Performance | Portfolio |
Börsenplätze | Performance | Management | Volatilität | Watchlist |
Historisch | Benchmark | Dokumente | Sharpe Ratio | |
Rendite | Ratings |
Kurse
Charts
Stammdaten
Kennzahlen
Nettoinventarwert (NAV)
10.14 USD | 0.07 USD | 0.68 % |
---|
Vortag | 10.07 USD | Datum | 19.11.2024 |
Fundamentaldaten
Fondsgesellschaft | LGIM Managers (Europe) Limited |
Benchmark | Solactive Pharma Breakthrough V NR USD |
Kategorie | Branchen: Biotechnologie |
Ausschüttung | Thesaurierend |
Replikation | Physisch vollständig |
Währung | USD |
Fondsvolumen | 14’572’171.19 |
Total Expense Ratio (TER) | 0.49 % |
Auflagedatum | 18.01.2018 |
Mindestanlage | |
Depotbank | Bank of New York Mellon SA/NV, Dublin Branch |
Zahlstelle |
Anlagepolitik
So investiert der L&G Pharma Breakthrough UCITS ETF: The investment objective of the Fund is to provide exposure to bio-technology companies that are actively engaged in the research, development and/or manufacturing of orphan drugs. In order to achieve this investment objective, the Fund will seek to track the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the “Index”). It will do so by investing primarily in a portfolio of equity securities that, as far as possible and practicable, consists of the component securities of the Index in similar proportions to their weightings in the Index and may have exposure to or invest directly up to 20% of its Net Asset Value in shares issued by the same body, which limit may be raised to 35% for a single issuer in exceptional market conditions, including (but not limited to) circumstances in which such issuer occupies a dominant market position.
Zusammensetzung nach Instrumenten
Zusammensetzung nach Branchen
Zusammensetzung nach Ländern
Zusammensetzung nach Holdings
Werbung
Günstige und zentrale Bausteine für Ihr Portfolio
Name | TER / Perf. YTD |
---|---|
Amundi Prime All Country World UCITS ETF Inc | 0.07 10.16 % |
Amundi S&P 500 Equal Weight ESG Leaders UCITS ETF DR USD Acc | 0.18 14.35 % |
Amundi S&P Global Consumer Staples ESG UCITS ETF DR EUR Acc | 0.18 7.72 % |
Amundi S&P 500 II UCITS ETF CHF Hedged Dist | 0.07 20.31 % |
Amundi Index Solutions - Amundi MSCI Europe Ex Switzerland ESG Leaders UCITS ETF-C DR | 0.14 5.09 % |
L&G Pharma Breakthrough UCITS ETF aktueller Kurs
10.14 USD | 0.07 USD | 0.68 % |
---|
Datum | |
Vortag | 0.00 USD |
Börse |
Fonds Performance: L&G Pharma Breakthrough UCITS ETF
Performance 1 Jahr | 1.74 | |
Performance 2 Jahre | -9.43 | |
Performance 3 Jahre | -22.49 | |
Performance 5 Jahre | 0.53 | |
Performance 10 Jahre | - |
Dokumente
powered byFondsgesellschaft
Name | LGIM Managers (Europe) Limited |
Postfach | 33/34 Sir John Rogerson’s Quay |
PLZ | |
Ort | |
Land | |
Telefon | |
Fax | |
URL | http://https://www.lgim.com/ |